SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ekkehard Bayerdörffer, Marc-Andre Bigard, Werner Weiss, Fermín Mearin, Luis Rodrigo, Juan Enrique Dominguez Muñoz, Hennie Grundling, Tore Persson, Lars-Erik Svedberg, Nanna Keeling, Stefan Eklund, Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease, BMC Gastroenterology, 2016, 16, 1

    CrossRef

  2. 2
    Françoise Goirand, Isabelle Le Ray, Marc Bardou, Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease, Expert Opinion on Drug Metabolism & Toxicology, 2014, 10, 9, 1301

    CrossRef

  3. 3
    Jung Ho Park, Hyojin Park, Dong Ho Lee, In Kyung Sung, A Randomized, Double Blinded, Clinical Trial to Assess the Efficacy and Cost Effectiveness of Omeprazole Compared to Rabeprazole in the Maintenance Therapy of Patients With Gastroesophageal Reflux Disease, Journal of Neurogastroenterology and Motility, 2013, 19, 2, 219

    CrossRef

  4. 4
    Berhanu Alemayehu, Xiongkan Ke, Nader N. Youssef, Joseph A. Crawley, Douglas S. Levine, Esomeprazole Formulary Exclusion: Impact on Total Health Care Services Use and Costs, Postgraduate Medicine, 2012, 124, 3, 149

    CrossRef

  5. You have free access to this content5
    P. Malfertheiner, M. Nocon, M. Vieth, M. Stolte, D. Jaspersen, H. R. Koelz, J. Labenz, A. Leodolter, T. Lind, K. Richter, S. N. Willich, Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care – the ProGERD study, Alimentary Pharmacology & Therapeutics, 2012, 35, 1
  6. 6
    Doença do refluxo gastroesofágico: tratamento farmacológico, Revista da Associação Médica Brasileira, 2011, 57, 6, 617

    CrossRef

  7. 7
    Gastroesophageal reflux disease: drug therapy, Revista da Associação Médica Brasileira (English Edition), 2011, 57, 6, 603

    CrossRef

  8. 8
    Gastroesophageal reflux disease: drug therapy, Revista da Associação Médica Brasileira, 2011, 57, 6, 603

    CrossRef

  9. 9
    S. Miehlke, S. Löbe, A. Madisch, E. Kuhlisch, M. Laass, D. Großmann, H. Knoth, A. Morgner, J. Labenz, Intragastric acidity during administration of generic omeprazole or esomeprazole – a randomised, two-way crossover study including CYP2C19 genotyping, Alimentary Pharmacology & Therapeutics, 2011, 33, 4
  10. 10
    David Armstrong, Daniel Sifrim, New Pharmacologic Approaches in Gastroesophageal Reflux Disease, Thoracic Surgery Clinics, 2011, 21, 4, 557

    CrossRef

  11. 11
    Peter J Kahrilas, Colin W Howden, Nesta Hughes, Response of Regurgitation to Proton Pump Inhibitor Therapy in Clinical Trials of Gastroesophageal Reflux Disease, The American Journal of Gastroenterology, 2011, 106, 8, 1419

    CrossRef

  12. 12
    A. H. Dabholkar, C. Han, M. M. Paris, M. C. Perez, S. N. Atkinson, D. A. Peura, The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease, Alimentary Pharmacology & Therapeutics, 2011, 33, 3
  13. 13
    Akihito Nagahara, Mariko Hojo, Daisuke Asaoka, Sumio Watanabe, Maintenance therapy of gastroesophageal reflux disease, Clinical Journal of Gastroenterology, 2010, 3, 2, 61

    CrossRef

  14. 14
    David Armstrong, Daniel Sifrim, New Pharmacologic Approaches in Gastroesophageal Reflux Disease, Gastroenterology Clinics of North America, 2010, 39, 3, 393

    CrossRef

  15. 15
    Stanislas Bruley des Varannes, Emmanuel Coron, Jean-Paul Galmiche, Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs?, Best Practice & Research Clinical Gastroenterology, 2010, 24, 6, 905

    CrossRef

  16. 16
    D. C. METZ, C. W. HOWDEN, M. C. PEREZ, L. LARSEN, J. O’NEIL, S. N. ATKINSON, Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis, Alimentary Pharmacology & Therapeutics, 2009, 29, 7
  17. 17
    C. W. HOWDEN, L. M. LARSEN, M. C. PEREZ, R. PALMER, S. N. ATKINSON, Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis – maintenance of healing and symptom relief, Alimentary Pharmacology & Therapeutics, 2009, 30, 9
  18. 18
    J. LABENZ, D. ARMSTRONG, S. ZETTERSTRAND, S. EKLUND, A. LEODOLTER, Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis - results from the maintenance phase of the EXPO study, Alimentary Pharmacology & Therapeutics, 2009, 29, 11
  19. 19
    J. LABENZ, D. ARMSTRONG, S. ZETTERSTRAND, S. EKLUND, A. LEODOLTER, Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis – results from the EXPO study, Alimentary Pharmacology & Therapeutics, 2009, 29, 9
  20. 20
    Takahisa Furuta, Mitsushige Sugimoto, Chise Kodaira, Masafumi Nishino, Mihoko Yamade, Mutsuhiro Ikuma, Naohito Shirai, Hiroshi Watanabe, Kazuo Umemura, Michio Kimura, Akira Hishida, CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole, European Journal of Clinical Pharmacology, 2009, 65, 7, 693

    CrossRef

  21. 21
    Ravi Vachhani, Gregory Olds, Vic Velanovich, Esomeprazole: a proton pump inhibitor, Expert Review of Gastroenterology & Hepatology, 2009, 3, 1, 15

    CrossRef

  22. 22
    Consuelo L Saccar, The pharmacology of esomeprazole and its role in gastric acid related diseases, Expert Opinion on Drug Metabolism & Toxicology, 2009, 5, 9, 1113

    CrossRef

  23. 23
    John Birk, Ronald Pruitt, Gregory Haber, Isaac Raijman, Arthur Baluyut, Mick Meiselman, Shahriar Sedghi, The Plicator procedure for the treatment of gastroesophageal reflux disease: a registry study, Surgical Endoscopy, 2009, 23, 2, 423

    CrossRef

  24. 24
    John Dent, Endoscopic grading of reflux oesophagitis: The past, present and future, Best Practice & Research Clinical Gastroenterology, 2008, 22, 4, 585

    CrossRef

  25. 25
    F. Argelles Arias, J.M. Garca Montes, J.M. Herreras Gutirrez, Enfermedad por reflujo gastroesof?gico, Medicine - Programa de Formaci?n M?dica Continuada Acreditado, 2008, 10, 1, 1

    CrossRef

  26. 26
    Kate McKeage, Stephanie K A Blick, Jamie D Croxtall, Katherine A Lyseng-Williamson, Gillian M Keating, Esomeprazole, Drugs, 2008, 68, 11, 1571

    CrossRef

  27. 27
    Ozlen Atug, Adnan Giral, Cem Kalayci, Enver Dolar, Fahri Isitan, Dilek Oguz, Oya Ovunc, Orhan Ozgur, Irfan Soykan, Ilkay Simsek, Selahattin Unal, Necati Yenice, Esomeprazole in acute and maintenance treatment of reflux oesophagitis: a multicentre prospective study, Advances in Therapy, 2008, 25, 6, 552

    CrossRef

  28. 28
    Santino Marchi, Nicola de Bortoli, Esperienza di un centro di endoscopia a un anno dall’introduzione delle delibere regionali in materia di adozione di lansoprazolo come farmaco di riferimento per gli inibitori di pompa protonica, PharmacoEconomics Italian Research Articles, 2008, 10, 1, 55

    CrossRef

  29. 29
    Lennart Estborn, Svante Joelson, Occurrence of Community-Acquired Respiratory Tract Infection in Patients Receiving Esomeprazole, Drug Safety, 2008, 31, 7, 627

    CrossRef

  30. 30
    David Armstrong, Norma Marchetti, Pharmacist-specific guidelines for the medical management of GERD in adults*, Canadian Pharmacists Journal, 2008, 141, sp1, S10

    CrossRef

  31. 31
    Clive Wilder-Smith, Tore Lind, Christina Lundin, Emma Nauclér, Catharina Nilsson-Pieschl, Kerstin Röhss, Acid control with esomeprazole and lansoprazole: A comparative dose–response study, Scandinavian Journal of Gastroenterology, 2007, 42, 2, 157

    CrossRef

  32. 32
    David C. Metz, Mark B. Sostek, Philippe Ruszniewski, Christopher E. Forsmark, John Monyak, Joseph R. Pisegna, Effects of Esomeprazole on Acid Output in Patients With Zollinger-Ellison Syndrome or Idiopathic Gastric Acid Hypersecretion, The American Journal of Gastroenterology, 2007, 102, 12, 2648

    CrossRef

  33. 33
    Khean-Lee Goh, Robert Benamouzig, Peter Sander, Thomas Schwan, Efficacy of pantoprazole 20???mg daily compared with esomeprazole 20???mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial ??? the EMANCIPATE study, European Journal of Gastroenterology & Hepatology, 2007, 19, 3, 205

    CrossRef

  34. 34
    Marcello Tonini, Il trattamento delle patologie acido-correlate ai tempi delle delibere regionali sull’equivalenza terapeutica dei PPI, PharmacoEconomics Italian Research Articles, 2007, 9, 2, 127

    CrossRef

  35. 35
    Alvaro Reymunde, Nilda Santiago, Long-term results of radiofrequency energy delivery for the treatment of GERD: sustained improvements in symptoms, quality of life, and drug use at 4-year follow-up, Gastrointestinal Endoscopy, 2007, 65, 3, 361

    CrossRef

  36. 36
    M. Tonini, S. Vigneri, M. Neri, R. Cuomo, V. Savarino, F. Pace, Potential Options to Optimize Therapy of Gastroesophageal Reflux Disease with Proton Pump Inhibitors, Digestion, 2007, 76, 3-4, 171

    CrossRef

  37. 37
    P. Lindberg, Comprehensive Medicinal Chemistry II, 2007,

    CrossRef

  38. 38
    Henry Cohen, Joaquim Prado P. Moraes-Filho, Maria Luisa Cafferata, Giselle Tomasso, Graciela Salis, Oscar Gonz??lez, Jorge Valenzuela, Prateek Sharma, Peter Malfertheiner, David Armstrong, Lars Lundell, Rodolfo Corti, Paulo Sakai, Ivan Ceconello, An evidence-based, Latin-American consensus on gastro-oesophageal reflux disease, European Journal of Gastroenterology & Hepatology, 2006, 18, 4, 349

    CrossRef

  39. 39
    Kenneth R. DeVault, John F. Johanson, David A. Johnson, Sherry Liu, Mark B. Sostek, Maintenance of Healed Erosive Esophagitis: A Randomized Six-Month Comparison of Esomeprazole Twenty Milligrams With Lansoprazole Fifteen Milligrams, Clinical Gastroenterology and Hepatology, 2006, 4, 7, 852

    CrossRef

  40. 40
    P. O. KATZ, J. M. SCHEIMAN, A. N. BARKUN, Review article: acid-related disease – what are the unmet clinical needs?, Alimentary Pharmacology & Therapeutics, 2006, 23,
  41. 41
    L.-Q. Chen, P. Ferraro, J. Martin, A. C. Duranceau, Antireflux surgery for Barrett's esophagus: comparative results of the Nissen and Collis-Nissen operations, Diseases of the Esophagus, 2005, 18, 5
  42. 42
    J Enrique Dom??nguez-Mu??oz, Miguel Sobrino, Clinical Response (Remission of Symptoms) in Erosive and Non-Erosive Gastro-Oesophageal Reflux Disease, Drugs, 2005, 65, Supplement 1, 43???50

    CrossRef

  43. 43
    E. Remák, R. E. Brown, C. Yuen, A. Robinson, Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK, Current Medical Research and Opinion, 2005, 21, 10, 1505

    CrossRef

  44. 44
    J. LABENZ, D. ARMSTRONG, K. LAURITSEN, P. KATELARIS, S. SCHMIDT, K. SCHÜTZE, G. WALLNER, H. JUERGENS, H. PREIKSAITIS, N. KEELING, E. NAUCLÉR, J. ADLER, S. EKLUND, Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study, Alimentary Pharmacology & Therapeutics, 2005, 22, 9
  45. 45
    A Morgner-Miehlke, KU Petersen, S Miehlke, J Labenz, Esomeprazole: potent acid suppression in the treatment of acid-related disorders, Expert Review of Clinical Immunology, 2005, 1, 4, 511

    CrossRef

  46. 46
    S. Miehlke, A. Madisch, C. Kirsch, F. Lindner, E. Kuhlisch, M. Laass, H. Knoth, A. Morgner, J. Labenz, Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily – a randomized, two-way crossover study, Alimentary Pharmacology & Therapeutics, 2005, 21, 8
  47. 47
    Miguel Bixquert, Maintenance Therapy in Gastro-oesophageal Reflux Disease, Drugs, 2005, 65, Supplement 1, 59???66

    CrossRef

  48. 48
    Brigitte Schumacher, Horst Neuhaus, Marianne Ortner, Ren?? Laugier, Martin Benson, Jean Boyer, Thierry Ponchon, Friedrich Hagenm??ller, Jean-Charles Grimaud, Patrick Rampal, Jean-Francois Rey, Karl-Hermann Fuchs, Hans-Peter Allgaier, J??rgen Hochberger, Hubert J Stein, Juan Andr??s Ram??rez Armengol, Peter D Siersema, Jacques Devi??re, Reduced Medication Dependency and Improved Symptoms and Quality of Life 12 Months After Enteryx Implantation for Gastroesophageal Reflux, Journal of Clinical Gastroenterology, 2005, 39, 3, 212

    CrossRef

  49. 49
    Philip O. Katz, Use of Intragastric pH Monitoring in Gastroesophageal Reflux Disease, Gastrointestinal Endoscopy Clinics of North America, 2005, 15, 2, 277

    CrossRef

  50. 50
    C. Negrini, P. Wahlqvist, C. Rossi, A. Dubini, V. Savarino, Valutazione economica della terapia di mantenimento al bisogno con esomeprazolo nella malattia da reflusso gastroesofageo, PharmacoEconomics Italian Research Articles, 2005, 7, 1, 67

    CrossRef

  51. 51
    Kerstin R??hss, Clive Wilder-Smith, Emma Naucl??r, Lennart Jansson, Esomeprazole 20mg Provides More Effective Intragastric Acid Control than Maintenance-Dose Rabeprazole, Lansoprazole or Pantoprazole in Healthy Volunteers, Clinical Drug Investigation, 2004, 24, 1, 1

    CrossRef

  52. 52
    Kerstin R�hss, Tore Lind, Clive Wilder-Smith, Esomeprazole 40�mg provides more effective intragastric acid control than lansoprazole 30�mg, omeprazole 20�mg, pantoprazole 40�mg and rabeprazole 20�mg in patients with gastro-oesophageal reflux symptoms, European Journal of Clinical Pharmacology, 2004, 60, 8, 531

    CrossRef

  53. 53
    Jean-Dominique de Korwin, Philippe Ducrotté, Thierry Vallot, Les nouveaux inhibiteurs de la pompe à protons, un progrès dans la prise en charge des maladies acido-peptiques ?, La Presse Médicale, 2004, 33, 11, 746

    CrossRef

  54. 54
    D. Armstrong, Review article: gastric pH — the most relevant predictor of benefit in reflux disease?, Alimentary Pharmacology & Therapeutics, 2004, 20,
  55. 55
    D. Armstrong, Review article: towards consistency in the endoscopic diagnosis of Barrett's oesophagus and columnar metaplasia, Alimentary Pharmacology & Therapeutics, 2004, 20,
  56. 56
    A. Papazian, A propos de l'article de Christian Florent «Inhibiteurs de la pompe à protons: la nouvelle génération»: quelques questions élémentaires d'un praticien, Acta Endoscopica, 2003, 33, 2, 273

    CrossRef

  57. 57
    Anan S. Raghunath, Jonathan R.B. Green, Steven J. Edwards, A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis, Clinical Therapeutics, 2003, 25, 7, 2088

    CrossRef

  58. 58
    Gabriella Der, An Overview of Proton Pump Inhibitors, Gastroenterology Nursing, 2003, 26, 5, 182

    CrossRef

  59. 59
    N. Vakil, M. B. Fennerty, Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease, Alimentary Pharmacology & Therapeutics, 2003, 18, 6
  60. 60
    Clare Donnellan, Cathy Preston, Paul Moayyedi, Nav Sharma, Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease, The Cochrane Library,
  61. 61
    Clare Donnellan, Cathy Preston, Paul Moayyedi, Nav Sharma, Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease, The Cochrane Library,